Pointstate Capital Lp buys $49,726,000 stake in Ariad Pharmaceuticals (ARIA)

Ariad Pharmaceuticals (ARIA) : Pointstate Capital Lp scooped up 450,000 additional shares in Ariad Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 4,700,000 shares of Ariad Pharmaceuticals which is valued at $49,726,000.Ariad Pharmaceuticals makes up approximately 1.27% of Pointstate Capital Lp’s portfolio.

Other Hedge Funds, Including , Tudor Investment Corp Et Al boosted its stake in ARIA in the latest quarter, The investment management firm added 7,400 additional shares and now holds a total of 27,069 shares of Ariad Pharmaceuticals which is valued at $286,390. Ariad Pharmaceuticals makes up approx 0.01% of Tudor Investment Corp Et Al’s portfolio. Formidable Asset Management added ARIA to its portfolio by purchasing 13,480 company shares during the most recent quarter which is valued at $142,618. Ariad Pharmaceuticals makes up approx 0.08% of Formidable Asset Management’s portfolio.Oxford Asset Management reduced its stake in ARIA by selling 225,922 shares or 22.95% in the most recent quarter. The Hedge Fund company now holds 758,519 shares of ARIA which is valued at $7,706,553. Ariad Pharmaceuticals makes up approx 0.30% of Oxford Asset Management’s portfolio.Quantitative Investment Management reduced its stake in ARIA by selling 14,400 shares or 14.46% in the most recent quarter. The Hedge Fund company now holds 85,200 shares of ARIA which is valued at $846,036. Ariad Pharmaceuticals makes up approx 0.04% of Quantitative Investment Management’s portfolio.

Ariad Pharmaceuticals closed down -0.15 points or -1.45% at $10.19 with 25,49,575 shares getting traded on Thursday. Post opening the session at $10.33, the shares hit an intraday low of $10.06 and an intraday high of $10.37 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Ariad Pharmaceuticals reported $0.59 EPS for the quarter, beating the analyst consensus estimate by $ 0.70 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $-0.11. The company had revenue of $68.13 million for the quarter, compared to analysts expectations of $62.11 million. The company’s revenue was up 133.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.

ARIAD Pharmaceuticals Inc. is a global oncology company. The Company is engaged in the discovery development and commercialization of small molecule drug indicated for the treatment of cancer. The Company’s product pipeline includes Iclusig (ponatinib) brigatinib (AP26113) AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI) which is approved in the United States Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788 is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Leave a Reply

Ariad Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Ariad Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.